Growth hormone axis
Tesamorelin
An approved medicine for one specific indication, routinely marketed for a much broader one.
Also known as: Egrifta, TH9507, GHRH analogue
Evidence passport
Last reviewed 2026-08-23
- Evidence level
- L4Strong human
- Confidence
- Moderate confidence
- Human efficacy
- 70/100
- Human safety
- 65/100
- Regulatory status
- Approved — narrow indication
- Development
- Approved
- Routes
- SC injection
- Evidence base
- Includes human data
- Furthest stage
- Approved
- Source curation
- Sources fully curated
- Clinical maturity
- Approved for a defined indication with Phase 3 support
Overview
Clinical maturity: Approved for a defined indication with Phase 3 support
Routes & formulations
Studied / approved routes
The approved product is a subcutaneous injection studied in the labelled HIV-associated lipodystrophy population.
Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.
Peptide lifecycle
Discovery
Preclinical
Phase I
Phase II
Phase III
Approved
Approved for HIV-associated lipodystrophy; broader uses remain unapproved.
What it is
A stabilised analogue of growth-hormone-releasing hormone that stimulates the pituitary to release growth hormone in a relatively physiological pattern.
What people claim
- Reduces visceral fat
- Improves body composition in healthy adults
- Anti-ageing and cognitive benefits
What the evidence actually says
Within its approved indication, tesamorelin has real randomised evidence for reducing visceral adipose tissue. Outside it, the evidence thins quickly: studies in healthy or general populations are limited, and the anti-ageing framing runs well past the data. Visceral fat reduction is also a surrogate endpoint, not a guaranteed health outcome.
Human evidence
- Randomised placebo-controlled trials in HIV-associated lipodystrophy showing visceral fat reduction.
- Smaller exploratory studies in other populations, including cognition-related work, that are not practice-changing.
Preclinical evidence
- Established GHRH-receptor pharmacology and growth-hormone axis physiology.
Animal and cell findings are Level 1–2 evidence.
Mechanism and pathways
- GHRH receptor agonism at the pituitary increases pulsatile growth hormone release.
- Downstream IGF-1 elevation drives lipolysis in visceral fat.
Safety and unknowns
- Common: injection-site reactions, joint pain, fluid retention, paraesthesia.
- Raises IGF-1, requiring monitoring; effects on glucose metabolism can be unfavourable in some people.
- Benefits reverse after stopping.
Cancer relevance
Monitored in trials; not demonstrated in humans
Regulatory status
Approved in the US (Egrifta WR) for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label states it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. General body-recomposition or anti-ageing use is off-label.
- Baseline · United States
Approved for excess visceral abdominal fat in HIV-associated lipodystrophy only.
Evidence grade
Solid controlled human trials, though not yet definitive or fully replicated.
What would change our rating?
- Long-term outcome data beyond surrogate imaging endpoints.
- Controlled trials in non-HIV populations.
References and sources
Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.
Evidence change history
No recorded changes yet. Baseline position set on 2026-08-23.